Poxel Looks To More Twymeeg Partnerships In Asia To Pay Off Debt
Following Japanese Market Success
Executive Summary
The French firm’s antidiabetic drug has enjoyed some traction in the Japanese market following the end of launch year restrictions, raising hopes that other Asian partnerships could help improve its financial position.
You may also be interested in...
Finance Watch: Syndax Has A Standout Post-ASH Offering As Peers Scramble For Cash
Public Company Edition: Syndax grossed $230m in a follow-on public offering based on positive results for its menin inhibitor in leukemia, but the FOPO was an outlier relative to other companies, which relied on private placements, debt and other options to raise cash in a tough market.
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.